Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13788446 | 0.83 | MAPT (0.42) | ALDH1A1MAPTNPSR1GALR2HPGD | |
| SCHEMBL13813006 | 0.82 | CTSB (0.47) | ALDH1A1MAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL6916314 | 0.81 | S100A4 (0.46) | ALDH1A1MAPTNPSR1GALR2HPGD | |
| SCHEMBL14538405 | 0.79 | HTT (0.42) | ALDH1A1MAPTNPSR1GALR2HPGD | |
| SCHEMBL14538438 | 0.79 | MAPT (0.41) | ALDH1A1MAPTSMN1; SMN2CYP3A4S100A4 | |
| SCHEMBL2988193 | 0.78 | S100A4 (0.46) | ALDH1A1MAPTNPSR1GALR2HPGD | |
| SCHEMBL221077 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPTNPSR1CYP3A4S100A4 | |
| SCHEMBL6916316 | 0.75 | KMT2A (0.53) | ALDH1A1MAPTSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL1359969 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MAPTNPSR1GALR2HPGD | |
| SCHEMBL13708975 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MAPTNPSR1GALR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215081-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AMINOBENZIMIDAZOLE UREAS | Vertex Pharmaceuticals Incorporated (US) | 2010-08-11 | — | — | EP | claimed |
| US-20090149651-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AMINOBENZIMIDAZOLE UREAS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-06-11 | — | — | US | claimed |
| WO-2009061875-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AMINOBENZIMIDAZOLE UREAS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-14 | — | — | WO | claimed |
| US-8404852-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-26 | — | — | US | disclosed |
| US-8394803-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394803-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394803-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130030004-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2013-01-31 | — | — | US | disclosed |
| US-20130030004-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2013-01-31 | — | — | US | disclosed |
| US-20130030004-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2013-01-31 | — | — | US | disclosed |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2007056330-A1 | BENZIMIDAZOLE DERIVATIVES AS GYRASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060122196-A9 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| WO-2006022773-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060025424-A1 | Gyrase inhibitors and uses thereof | CHARIFSON PAUL | 2006-02-02 | — | — | US | disclosed |
| US-20050256136-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-11-17 | — | — | US | disclosed |
| EP-1592686-A1 | GYRASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050038247-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-02-17 | — | — | US | disclosed |
| WO-2005012292-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040235886-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122196-A9 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALDH1A1 3787/4885MAPT 3810/4885NPSR1 4869/4885 |
| US-20130030004-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALDH1A1 3184/4885MAPT 3439/4885NPSR1 4829/4885 |
| US-20040235886-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALDH1A1 3801/4885MAPT 3821/4885NPSR1 4868/4885 |
| US-20060025424-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALDH1A1 3787/4885MAPT 3810/4885NPSR1 4869/4885 |
| US-20090149651-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AMINOBENZIMIDAZOLE UREAS | TOP2B, TOP1, TOP2A | ALDH1A1 3384/4885MAPT 1817/4885NPSR1 4844/4885 |
| US-20050256136-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, NQO2 | ALDH1A1 1650/4885MAPT 4342/4885NPSR1 4774/4885 |
| US-20130023525-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | ALDH1A1 3801/4885MAPT 3821/4885NPSR1 4868/4885 |
| US-20050038247-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALDH1A1 3787/4885MAPT 3810/4885NPSR1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.